It has previously been demonstrated that some therapy relevant properties of MSCs such as inhibition of T cell proliferation and CD73 expression do change over passage, but in these studies, we found that overall therapeutic efficacy in ARDS was lost beyond passage 3. Here, NT5E is linked to acute respiratory distress syndrome.